Table 3. Key points of vaccination in biologics-treated Kawasaki disease

1. Biologic agents, including infliximab, may affect immune responses in children treated for Kawasaki disease.2. Live-attenuated vaccines are contraindicated during biologic therapy because of potential safety concerns.3. Inactivated vaccines (e.g., influenza) can be administered as needed according to the standard immunization schedule.4. Live-attenuated vaccines can generally be administered 6 months after treatment with biological agents, including infliximab.